Cocrystal Pharma (COCP) Expected to Release Quarterly Earnings on Friday

Cocrystal Pharma (NASDAQ:COCP) is anticipated to announce its results on Friday, November 13th. Analysts expect the company to post earnings of ($0.17) per share and revenue of $0.10 million for the quarter.

Cocrystal Pharma (NASDAQ:COCP) last announced its earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.06). The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.10 million. On average, analysts expect Cocrystal Pharma to post ($0.69) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Cocrystal Pharma Stock Down 1.0%

COCP opened at $1.02 on Thursday. Cocrystal Pharma has a twelve month low of $0.76 and a twelve month high of $2.03. The company has a 50-day moving average price of $1.09 and a 200 day moving average price of $1.10. The company has a market cap of $19.65 million, a PE ratio of -1.34 and a beta of 1.60.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on COCP shares. Weiss Ratings cut Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. HC Wainwright restated a “buy” rating on shares of Cocrystal Pharma in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

About Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics. The company uses structure-based drug discovery and advanced medicinal chemistry to design small-molecule treatments intended to target viral replication mechanisms. Cocrystal’s research and development programs have focused primarily on infectious diseases, including influenza A and norovirus. Its pipeline has included orally administered antiviral candidates designed to inhibit viral polymerase proteins, as well as programs addressing other significant viral pathogens.